孕期新冠疫苗接种及与流感疫苗同时接种的反应原性:加拿大COVERED队列研究
加拿大COVERED前瞻性队列研究纳入2023年9月至2024年3月754名孕妇,其中344人(45.6%)孕期接种新冠疫苗,85人(24.7%)同日接种流感疫苗。同时接种组新冠注射部位反应(67.1% vs 42.1%,p<.01)和寒战(18.8% vs 8.5%,p=.03)报告率高于单独接种组,但未报告新的或加重的健康问题。孕期新冠疫苗接种无论是否同时接种流感疫苗均安全且耐受良好。
要点
- 孕期新冠疫苗与流感疫苗同时接种未报告新的或加重的健康问题。
- 同时接种组注射部位反应和寒战报告率高于单独接种组,但总体耐受良好。
- 孕期新冠疫苗接种后最常见不良事件为注射部位反应、疲劳和肌痛。
核心结论
- 孕期接种新冠疫苗无论是否同时接种流感疫苗均安全且耐受良好。
- 同时接种流感疫苗者新冠注射部位反应和寒战报告率更高,但无新的或加重的健康问题报告。
研究设计与样本
- 加拿大COVERED全国前瞻性队列研究,2023年9月至2024年3月纳入754名孕妇,无论接种状态。
- 通过系列在线问卷评估新冠疫苗接种后7天内的反应原性和显著健康事件,比较单独接种新冠疫苗与同时接种新冠和流感疫苗者。
主要发现
- 344名(45.6%)孕期接种新冠疫苗,其中85名(24.7%)同日接种流感疫苗。
- 接种后7天内最常见不良事件为局部注射部位反应(166/344,48.3%)、疲劳(139/344,40.4%)和肌痛(135/344,39.2%)。
- 同时接种组新冠注射部位反应报告率高于单独接种组(57/85,67.1% vs 109/259,42.1%,p<.01)。
- 同时接种组寒战报告率高于单独接种组(16/85,18.8% vs 22/259,8.5%,p=.03)。
- 同时接种新冠和流感疫苗后未报告新的或加重的健康问题。
临床怎么用
- 孕期可同时接种新冠疫苗和流感疫苗,未报告显著健康事件,有助于提高接种可及性和覆盖率。
- 应告知孕妇同时接种可能增加注射部位反应和寒战,但总体耐受良好。
局限性
- 反应原性和健康事件基于自我报告,可能存在报告偏倚。
- 同时接种组样本量较小(85人),部分比较的统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite consistent evidence of safety and efficacy of immunization against COVID-19, vaccine hesitancy remains prevalent among pregnant individuals. Reactogenicity (post-vaccination inflammatory symptoms) has been cited as a significant factor in decreasing vaccine acceptance. The seasonal overlap in the vaccination schedule for COVID-19 and influenza provides an opportunity to increase vaccine accessibility and uptake while decreasing healthcare burden through coadministration. METHODS: The Canadian COVID-19 Vaccine Registry for Pregnant Women and Pregnant People (COVERED) is a national prospective cohort study that enrolled pregnant participants in Canada, irrespective of vaccination status, from September 2023 to March 2024. Vaccine reactogenicity and significant health events (defined as a new or worsening health problem), within seven days of COVID-19 vaccination, were assessed using serial online surveys, and compared between those who received COVID-19 vaccine only and those who received concurrent COVID-19 and influenza vaccines (coadministration). RESULTS: Among 754 participants, 344 (45.6%) received COVID-19 vaccination during pregnancy, with 85 of 344 (24.7%) also receiving a same-day influenza vaccination. Within seven days of COVID-19 vaccination, the adverse events most reported were local injection site reaction (166/344 [48.3%]), fatigue (139/344 [40.4%]), and myalgia (135/344 [39.2%]). Increased rates of COVID-19 injection site reaction (57/85 [67.1%] vs. 109/259 [42.1%], p < .01) and chills (16/85 [18.8%] vs. 22/259 [8.5%], p = .03) were reported in those who received COVID-19 and influenza vaccines together when compared to those who received the COVID-19 vaccine alone. No new or worsening health problems were reported after coadministration of COVID-19 and influenza vaccines during pregnancy. CONCLUSIONS: COVID-19 vaccination in pregnancy, with or without influenza vaccine coadministration, was safe and well-tolerated by survey respondents. Local injection site reaction and chills were more common after COVID-19 vaccination in those who also received a same-day influenza vaccination. There were no reports of significant health events after COVID-19 and influenza vaccine coadministration.
引用
- Tran S, McClymont E, Blitz S, et al. Self-reported reactogenicity after COVID-19 vaccination with and without influenza vaccine coadministration during pregnancy in Canada. Vaccine. 2026. PMID: 42691825. doi:10.1016/j.vaccine.2026.129122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。